Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.53 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.35 |
| ▸ | IL1B | P01584 | 1/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1459309 | 1.00 | CHRNA7 (0.53) | CHRNA7TLR7IL1BNLRP3CHRM2 | |
| SCHEMBL1460490 | 0.94 | CHRNA7 (0.53) | CHRNA7TLR7IL1BNLRP3CHRM2 | |
| SCHEMBL1460488 | 0.94 | CHRNA7 (0.53) | CHRNA7TLR7IL1BNLRP3CHRM2 | |
| SCHEMBL1581827 | 0.87 | CHRNA7 (0.40) | CHRNA7IL1BNLRP3CHRM2CHRM1 | |
| SCHEMBL1145858 | 0.87 | CHRNA7 (0.40) | CHRNA7IL1BNLRP3CHRM2CHRM1 | |
| SCHEMBL1459282 | 0.87 | CHRNA7 (0.53) | CHRNA7TLR7CHRM2CHRM1 | |
| SCHEMBL1459280 | 0.87 | CHRNA7 (0.53) | CHRNA7TLR7CHRM2CHRM1 | |
| SCHEMBL3839228 | 0.87 | CHRNA7 (0.53) | CHRNA7TLR7CHRM2CHRM1 | |
| SCHEMBL3839223 | 0.87 | CHRNA7 (0.53) | CHRNA7TLR7CHRM2CHRM1 | |
| SCHEMBL3840240 | 0.84 | CHRNA7 (0.54) | CHRNA7CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2480228-B1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG (CH) | 2016-11-16 | — | — | EP | claimed |
| US-8236803-B2 | Aza-bicycloalkyl ethers and their use as alpha7-nAChR agonists | NOVARTIS AG (CH) | 2012-08-07 | — | — | US | claimed |
| EP-1537104-B1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | NOVARTIS AG (CH) | 2009-11-11 | — | — | EP | claimed |
| US-12215387-B2 | Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | NOVARTIS AG (CH) | 2025-02-04 | — | — | US | disclosed |
| US-20220316011-A1 | BIOMARKER PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | NOVARTIS AG (CH) | 2022-10-06 | — | — | US | disclosed |
| US-11359241-B2 | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | NOVARTIS AG (CH) | 2022-06-14 | — | — | US | disclosed |
| US-11311525-B2 | Use of alpha 7 nicotinic acetylcholine receptor agonists | NOVARTIS AG (CH) | 2022-04-26 | — | — | US | disclosed |
| US-20210338621-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG (CH) | 2021-11-04 | — | — | US | disclosed |
| EP-2945633-B1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2021-06-30 | — | — | EP | disclosed |
| US-20200108035-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG (CH) | 2020-04-09 | — | — | US | disclosed |
| US-20180037957-A1 | BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | NOVARTIS AG (CH) | 2018-02-08 | — | — | US | disclosed |
| US-20120157464-A1 | USE OF AZABICYCLOALKYL DERIVATIVES OR PYRROLIDINE-2-ONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF ATAXIA | NOVARTIS AG | 2012-06-21 | — | — | US | disclosed |
| EP-2332537-A1 | Combinations of nicotinic acetylcholine alpha 7 receptor agonists | Novartis AG (CH) | 2011-06-15 | — | — | EP | disclosed |
| WO-2011036167-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| US-20100125063-A1 | COMBINATIONS OF NICOTINIC ACETYLCHOLINE ALPHA 7 RECEPTOR AGONISTS | NOVARTIS AG | 2010-05-20 | — | — | US | disclosed |
| EP-2135609-A1 | Combinations of nicotinic acetylcholine alpha 7 receptor agonists | Novartis AG (CH) | 2009-12-23 | — | — | EP | disclosed |
| EP-1537104-B1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | NOVARTIS AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-20080306081-A1 | Combinations of Nicotinic Acetylcholine Alpha 7 Receptor Antagonists | NOVARTIS AG (CH) | 2008-12-11 | — | — | US | disclosed |
| EP-1809285-A1 | COMBINATIONS OF NICOTINIC ACETYLCHOLINE ALPHA 7 RECEPTOR AGONISTS | Novartis AG (CH) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006048294-A1 | COMBINATIONS OF NICOTINIC ACETYLCHOLINE ALPHA 7 RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11311525-B2 | Use of alpha 7 nicotinic acetylcholine receptor agonists | CHRNA7, CHRNA1, CHRNA5 | CHRNA7 1/4885TLR7 134/4885IL1B 1838/4885 |
| US-20180037957-A1 | BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | CHRNA7, CHRNA4, CHRNA5 | CHRNA7 1/4885TLR7 223/4885IL1B 648/4885 |
| US-12215387-B2 | Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | CHRNA7, CHRNA4, CHRNA5 | CHRNA7 1/4885TLR7 238/4885IL1B 695/4885 |
| US-20100125063-A1 | COMBINATIONS OF NICOTINIC ACETYLCHOLINE ALPHA 7 RECEPTOR AGONISTS | CHRNA7, CHRNA4, CHRNA10 | CHRNA7 1/4885TLR7 143/4885IL1B 3412/4885 |
| US-20220316011-A1 | BIOMARKER PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | CHRNA7, CHRNA4, CHRNA5 | CHRNA7 1/4885TLR7 238/4885IL1B 695/4885 |
| US-20200108035-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | CHRNA7, CHRNA5, CHRNA4 | CHRNA7 1/4885TLR7 193/4885IL1B 2523/4885 |
| US-20080306081-A1 | Combinations of Nicotinic Acetylcholine Alpha 7 Receptor Antagonists | CHRNA7, CHRNA4, CHRNA10 | CHRNA7 1/4885TLR7 188/4885IL1B 3559/4885 |
| US-20120157464-A1 | USE OF AZABICYCLOALKYL DERIVATIVES OR PYRROLIDINE-2-ONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF ATAXIA | ATXN2, CDR2, ATXN2L | CHRNA7 205/4885TLR7 3961/4885IL1B 4122/4885 |
| US-11359241-B2 | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | CHRNA7, CHRNA4, CHRNA5 | CHRNA7 1/4885TLR7 223/4885IL1B 648/4885 |
| US-20210338621-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | CHRNA7, CHRNA5, CHRNA4 | CHRNA7 1/4885TLR7 193/4885IL1B 2523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.